Third Generation DNA synthesis: Unlock the power of biology
Synthetic biology is a term used to describe an approach by which novel artificial biological pathways, organisms or devices are designed and constructed. Bringing together skills from biology, chemistry, bioinformatics and engineering, it applies engineering-like techniques, at scale, to solve biological problems through a rational process of ‘biodesign’. With the potential to deliver a wide range of new and innovative products to several industries, including the pharmaceutical industry, synthetic biology presents the opportunity to exploit biology as never before, to transform the field of drug discovery. This will lead to the discovery of new medicines, which could potentially result in major improvements in healthcare and patient outcomes.
It is clear that synthetic biology has the potential to impact many aspects of drug discovery, but the scale of the impact will depend on the further development of its underlying technologies. These include DNA synthesis, powerful bioinformatics, suitable chassis organisms and the ability to build/engineer pathways and organisms in a predictable fashion. In the same way that DNA sequencing underwent a revolution in the mid-2000s resulting in massive parallelisation and reduction in cost, a comparable breakthrough in DNA synthesis would catalyse many opportunities in this area.
Evonetix is developing a third generation DNA synthesis platform that unlocks the power of biology to address many of the worlds most pressing needs including better healthcare. Our technology will enable a greater diversity of rationally designed drugs whilst decreasing the time to market, enhancing the ability to make more life-saving drugs more quickly.